Englander Institute for Precision Medicine

Weill Cornell Medicine is part of an international team that has been awarded funding of up to $25 million over five years by Cancer Grand Challenges to study the causes of cancer inequities.

Male breast cancer has distinct alterations in the tumor genome that may suggest potential treatment targets, according to a study by Weill Cornell Medicine investigators.

Weill Cornell Medicine researchers received a $2.4 million grant from the U.S. Department of Defense Breast Cancer Research Program to validate a new blood test for the early detection of breast cancer.

A historic investment from Board of Fellows member Israel Englander will advance Weill Cornell Medicine’s growing research enterprise and support critical initiatives throughout the institution. 

Located one block from Weill Cornell Medicine’s main campus on Manhattan’s Upper East Side, the site will add approximately 200,000 square feet of dedicated research space. 

Dr. Bishoy M. Faltas, the Gellert Family-John P. Leonard, M.D. Research Scholar and an assistant professor of medicine at Weill Cornell Medicine, has been awarded a $4 million, seven-year MERIT grant from the National Cancer Institute (NCI) at the National Institutes of Health (NIH).

Researchers at Weill Cornell Medicine have performed the most comprehensive analysis to date of cancer of the ureters or the urine-collection cavities in the kidney, known as upper tract urothelial carcinoma (UTUC). 

The designation adds the academic medical center to NORD’s collaborative network of 40 participating institutions that research and treat rare diseases.

An atlas that catalogues gene activity and the levels of small molecules called metabolites in tumor samples offers a new way of identifying the deep mechanisms of cancer, according to researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center.

Nearly 90 percent of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.

Dr. Omar Abdul-Rahman, a leading specialist in pediatric genetic medicine, has been named chief of the Division of Medical Genetics in the Department of Pediatrics at Weill Cornell Medicine and NewYork-Presbyterian Komansky Children’s Hospital, effective March 1.

An enzyme that defends human cells against viruses can help drive cancer evolution towards greater malignancy by causing myriad mutations in cancer cells.

An artificial intelligence algorithm can determine non-invasively, with about 70 percent accuracy, if an in vitro fertilized embryo has a normal or abnormal number of chromosomes.

A $20 million gift from Andrew H. ’71 and Ann R. Tisch will foster engagement and collaboration between Cornell Tech and Weill Cornell Medicine, catalyzing new discoveries at the intersection of health and technology.

Weill Cornell Medicine researchers have developed a computational method to map the architecture of human tissues in unprecedented detail.

Weill Cornell Medicine investigators have identified definitive biological links between African ancestry and disease processes that affect an aggressive cancer type called triple-negative breast cancer.

A collaboration between Weill Cornell Medicine scientists and other leaders in Alzheimer’s disease research has revealed widespread metabolic changes in the brains of individuals with Alzheimer’s disease. 

Artificial intelligence may soon help doctors diagnose and treat diseases, including cancer and depression, based on the sound of a patient’s voice, as 12 leading research institutions launch a landmark National Institutes of Health-funded academic project that may establish voice as a biomarker used in clinical care.

Weill Cornell Medicine and New York Genome Center researchers, in collaboration with Oxford Nanopore Technologies, have developed a new method to assess on a large scale the three-dimensional structure of the human genome, or how the genome folds.

Researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have identified a previously unrecognized form of hormone therapy-resistant prostate cancer, as well as a set of molecules that drive its growth. This discovery opens the door to the development of therapies that treat this specific disease.